Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

  • C Crawley
  • M Lalancette
  • R Szydlo
  • M Gilleece
  • K Peggs
  • S Mackinnon
  • Gunnar Juliusson
  • L Ahlberg
  • A Nagler
  • A Shimoni
  • A Sureda
  • JM Boiron
  • H Einsele
  • R Chopra
  • A Carella
  • J Cavenagh
  • A Gratwohl
  • F Garban
  • A Zander
  • B Bjorkstrand
  • D Niederwieser
  • G Gahrton
  • JF Apperley
Publiceringsår: 2005
Språk: Engelska
Sidor: 4532-4539
Publikation/Tidskrift/Serie: Blood
Volym: 105
Nummer: 11
Dokumenttyp: Artikel i tidskrift
Förlag: American Society of Hematology


We report the outcome of 229 patients who received an allograft for myeloma with reduced-intensity conditioning (RIC) regimens from 33 centers within the European Group for Blood and Marrow Transplantation (EBMT). The median age was 52 years and 64% were male. Conditioning regimens were heterogeneous, but most were fludarabine based and T cell depleted with antithymocyte globulin or alemtuzumab. Transplantation-related mortality (TRIM) at 1 year was 22%. The 3-year overall survival (OS) and progression-free survival (PFS) were 41% and 21 %, respectively. Adverse OS was associated with chemoresistant disease (relative risk [RR], 2.9), more than 1 prior transplantation (RR, 2.0), and male patients with female donors (FIR, 1.45). Adverse PFS was associated with chemoresistance (RR, 2.4) and alemtuzumab (RR, 1.8). TRM was increased with female-to-male donation (RR, 2.5) and transplantation more than 1 year from diagnosis (RR, 2.3). Grades II to IV acute graft-versus-host disease (aGvHD) occurred in 31%. Chronic GvHD was associated with better OS and PFS and were 84% and 46% for limited, 58% and 30% for extensive, and 29% and 12% in its absence suggesting that a graft-versus-myeloma effect is important. While RIC is feasible, heavily pretreated patients and patients with progressive disease do not benefit.


  • Hematology


  • ISSN: 1528-0020

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen